Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011, Article ID 854697, 12 pages
http://dx.doi.org/10.1155/2011/854697
Clinical Study

Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

1Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan
2Department of Pharmacy, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan

Received 22 June 2011; Accepted 19 August 2011

Academic Editor: Hiep T. Nguyen

Copyright © 2011 Masayoshi Zaitsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Abrams, L. Cardozo, M. Fall et al., “The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society,” Urology, vol. 61, no. 1, pp. 37–49, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Milsom, P. Abrams, L. Cardozo, R. G. Roberts, J. Thüroff, and A. J. Wein, “How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study,” BJU International, vol. 87, no. 9, pp. 760–766, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. W. F. Stewart, J. B. Van Rooyen, G. W. Cundiff et al., “Prevalence and burden of overactive bladder in the United States,” World Journal of Urology, vol. 20, no. 6, pp. 327–336, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. Y. Homma, O. Yamaguchi, and K. Hayashi, “An epidemiological survey of overactive bladder symptoms in Japan,” BJU International, vol. 96, no. 9, pp. 1314–1318, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. P. Abrams, C. J. Kelleher, L. A. Kerr, and R. G. Rogers, “Overactive bladder significantly affects quality of life,” American Journal of Managed Care, vol. 6, no. 11, supplement, pp. S580–S590, 2000. View at Google Scholar · View at Scopus
  6. C. R. Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder,” Urology, vol. 55, no. 5, supplement, pp. 33–46, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Kobayashi, Y. Yageta, M. Segawa, and S. Matsuzawa, “Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors: high affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland,” Arzneimittel-Forschung, vol. 57, no. 2, pp. 92–100, 2007. View at Google Scholar · View at Scopus
  8. F. Kobayashi, Y. Yageta, T. Yamazaki et al., “Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats: comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task,” Arzneimittel-Forschung, vol. 57, no. 3, pp. 147–154, 2007. View at Google Scholar · View at Scopus
  9. A. Ohtake, M. Ukai, T. Hatanaka et al., “In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats,” European Journal of Pharmacology, vol. 492, no. 2-3, pp. 243–250, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Ikeda, S. Kobayashi, M. Suzuki et al., “M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 366, no. 2, pp. 97–103, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. Kobayashi, K. Ikeda, and K. Miyata, “Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells,” Life Sciences, vol. 74, no. 7, pp. 843–853, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Madersbacher, M. Halaska, R. Voigt, S. Alloussi, and K. Höfner, “A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence,” BJU International, vol. 84, no. 6, pp. 646–651, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Diokno, R. A. Appell, P. K. Sand et al., “Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial,” Mayo Clinic Proceedings, vol. 78, no. 6, pp. 687–695, 2003. View at Google Scholar · View at Scopus
  14. Y. Homma, J. S. Paick, J. G. Lee, and K. Kawabe, “Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial,” BJU International, vol. 92, no. 7, pp. 741–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. R. Chapple, T. Rechberger, S. Al-Shukri et al., “Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder,” BJU International, vol. 93, no. 3, pp. 303–310, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. K. P. Jünemann, M. Halaska, T. Rittstein et al., “Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder,” European Urology, vol. 48, no. 3, pp. 478–482, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. R. Chapple, R. Martinez-Garcia, L. Selvaggi et al., “A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial,” European Urology, vol. 48, no. 3, pp. 464–470, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. R. U. Anderson, S. MacDiarmid, S. Kell, J. H. Barada, S. Serels, and R. P. Goldberg, “Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder,” International Urogynecology Journal and Pelvic Floor Dysfunction, vol. 17, no. 5, pp. 502–511, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. R. Chapple, A. Fianu-Jonsson, M. Indig et al., “Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg,” European Urology, vol. 52, no. 4, pp. 1195–1203, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. O. Yamaguchi, E. Marui, H. Kakizaki et al., “Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder,” BJU International, vol. 100, no. 3, pp. 579–587, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. S. Choo, J. Z. Lee, J. B. Lee et al., “Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study,” International Journal of Clinical Practice, vol. 62, no. 11, pp. 1675–1683, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. Y. Homma and O. Yamaguchi, “A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder,” International Journal of Urology, vol. 16, no. 5, pp. 499–506, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. Y. Homma and O. Yamaguchi, “Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder,” International Journal of Urology, vol. 15, no. 11, pp. 986–991, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. O. Yamaguchi, “Long-term safety and tolerability of solifenacin succinate in patients with overactive bladder,” Japanese Pharmacology and Therapeutics, vol. 34, pp. 69–86, 2006. View at Google Scholar
  25. P. D. Meek, S. D. Evang, M. Tadrous, D. Roux-Lirange, D. M. Triller, and B. Gumustop, “Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials,” Digestive Diseases and Sciences, vol. 56, no. 1, pp. 7–18, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. T. Oki, S. Sato, K. Miyata, and S. Yamada, “Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice,” British Journal of Pharmacology, vol. 145, no. 2, pp. 219–227, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. T. Oki, S. Maruyama, Y. Takagi, H. I. Yamamura, and S. Yamada, “Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice,” European Journal of Pharmacology, vol. 529, no. 1–3, pp. 157–163, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. Y. Ito, A. Kato, T. F. Fujino Oki et al., “Muscarinic receptor binding and plasma drug concentration after the oral administration of propiverine in mice,” Lower Urinary Tract Symptoms, vol. 2, no. 1, pp. 43–49, 2010. View at Publisher · View at Google Scholar
  29. S. Yamada, M. Seki, M. Ogoda, A. Fukata, M. Nakamura, and Y. Ito, “Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder,” Journal of Pharmacology and Experimental Therapeutics, vol. 336, no. 2, pp. 365–371, 2011. View at Publisher · View at Google Scholar · View at PubMed
  30. A. Wagg, G. Compion, E. Siddiqui, and A. Fahey, “Persistence patterns with oral antimuscarinics used for the treatment of overactive bladder in UK general practice: a retrospective analysis bya age,” in Proceedings of the Annual Meeting of International Continence Society/International Urogynecological Association (ICS/IUGA '10), Toronto, Canada, 2010.
  31. Y. Homma, M. Yoshida, N. Seki et al., “Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score,” Urology, vol. 68, no. 2, pp. 318–323, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. C. J. Kelleher, L. D. Cardozo, V. Khullar, and S. Salvatore, “A new questionnaire to assess the quality of life of urinary incontinent women,” British Journal of Obstetrics and Gynaecology, vol. 104, no. 12, pp. 1374–1379, 1997. View at Google Scholar